pharma · Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer · Acute Myeloid Leukemia
Stemline Therapeutics (United
Stemline Therapeutics B.V.
Stemline Therapeutics is a pharma organization headquartered in EU. Primary therapeutic focus areas include Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer, Acute Myeloid Leukemia, Advanced
New York, USA HQ
767 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York, USA
- Employees
- 767
- Programs
- 7
- Drugs
- 29
- Patents
- 0
ELA-0121
Phase 2 · small molecule · Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
ELA-0121 for Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer is a Phase 2 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Internal code ELA-0121
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Stemline Therapeutics B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer
- Status
- active
- Trials
- 1